Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Nov 25;14(1):183.
doi: 10.1186/s12916-016-0722-3.

How do you design randomised trials for smaller populations? A framework

Mahesh K B Parmar  1 , Matthew R Sydes  1 , Tim P Morris  2   3
Affiliations

How do you design randomised trials for smaller populations? A framework

Mahesh K B Parmar et al. BMC Med. .

Abstract

How should we approach trial design when we can get some, but not all, of the way to the numbers required for a randomised phase III trial?We present an ordered framework for designing randomised trials to address the problem when the ideal sample size is considered larger than the number of participants that can be recruited in a reasonable time frame. Staying with the frequentist approach that is well accepted and understood in large trials, we propose a framework that includes small alterations to the design parameters. These aim to increase the numbers achievable and also potentially reduce the sample size target. The first step should always be to attempt to extend collaborations, consider broadening eligibility criteria and increase the accrual time or follow-up time. The second set of ordered considerations are the choice of research arm, outcome measures, power and target effect. If the revised design is still not feasible, in the third step we propose moving from two- to one-sided significance tests, changing the type I error rate, using covariate information at the design stage, re-randomising patients and borrowing external information.We discuss the benefits of some of these possible changes and warn against others. We illustrate, with a worked example based on the Euramos-1 trial, the application of this framework in designing a trial that is feasible, while still providing a good evidence base to evaluate a research treatment.This framework would allow appropriate evaluation of treatments when large-scale phase III trials are not possible, but where the need for high-quality randomised data is as pressing as it is for common diseases.

Keywords: Randomised trials; Smaller populations; Trial design; Uncommon diseases.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
The framework for designing trials in smaller populations. Readers should use the corresponding subheadings in the text to understand the considerations for each element, particularly regarding context
Fig. 2
Fig. 2
Dependence of required number of patients on sidedness of tests and desired type I error rate
See this image and copyright information in PMC

References

    1. Gagne JJ, Thompson L, O’Keefe K, Kesselheim AS. Innovative research methods for studying treatments for rare diseases: methodological review. BMJ. 2014;349:6802. doi: 10.1136/bmj.g6802. - DOI - PMC - PubMed
    1. Rustin GJS, van der Burg MEL, Griffin CL, Guthrie D, Lamont A, Jayson GC, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet. 2010;376(9747):1155–63. doi: 10.1016/S0140-6736(10)61268-8. - DOI - PubMed
    1. Bogaerts J, Sydes MR, Keat N, McConnell A, Benson A, Ho A, et al. Clinical trial designs for rare diseases: studies developed and discussed by the international rare cancers initiative. Eur J Cancer. 2015;51(3):271–81. doi: 10.1016/j.ejca.2014.10.027. - DOI - PMC - PubMed
    1. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer. 1976;34(6):585–612. doi: 10.1038/bjc.1976.220. - DOI - PMC - PubMed
    1. Cook J, Hislop J, Adewuyi T, Harrild K, Altman D, Ramsay C, et al. Assessing methods to specify the target difference for a randomised controlled trial: DELTA (difference ELicitation in TriAls) review. Health Technol Assess. 2014;18(28):1–166. doi: 10.3310/hta18280. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources